# Recombinant vWF Concentrate and ECMO

> **NCT06118372** · PHASE1 · RECRUITING · sponsor: **University of Virginia** · enrollment: 12 (estimated)

## Conditions studied

- Bleeding Disorder

## Interventions

- **DRUG:** Recombinant von Willebrand Factor

## Key facts

- **NCT ID:** NCT06118372
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-03
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-02-28
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118372, "Recombinant vWF Concentrate and ECMO". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06118372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*